Skip to main content
Erschienen in: International Journal of Hematology 2/2012

01.02.2012 | Original Article

Prevalence of monoclonal gammopathy of undetermined significance in Thailand

verfasst von: Phandee Watanaboonyongcharoen, Thanyaphong Na Nakorn, Ponlapat Rojnuckarin, Panisinee Lawasut, Tanin Intragumtornchai

Erschienen in: International Journal of Hematology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Individuals with monoclonal gammopathy of undetermined significance (MGUS) develop multiple myeloma and related malignancies at the rate of 1% per year. Given differences in ethnicity, data on prevalence and risk factors of MGUS in Thai population will be helpful in understanding the pathogenesis of plasma cell disorders and designing an early cancer detection strategy. Subjects of 50 years or older were included. Demographic data and suspected risk factors were collected. Monoclonal proteins were detected using serum protein electrophoresis. Serum was obtained from 3,260 participants; 1,104 males (33.9%) and 2,156 females (66.1%). The median age was 57 years (range 50–93 years). Monoclonal proteins were detectable in 2.3% (95% confidence interval [CI] 1.8–2.8). M spikes were found in gamma- and beta-globulin regions in 50 (1.5%) and 25 (0.8%) subjects, respectively. The prevalence of MGUS in subjects 50–59, 60–69, and 70 years or older was 2.0% (41/1,975), 2.6% (22/851), and 2.8% (12/434), respectively. By multivariate analysis, MGUS was associated with living outside Bangkok (odds ratio 2.25, 95% CI 1.11–4.58). The overall prevalence of MGUS in the Thai population was 2.3%, which was lower than that in Western countries, but comparable to that in Japan.
Literatur
1.
Zurück zum Zitat Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20:637–64.PubMedCrossRef Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20:637–64.PubMedCrossRef
2.
Zurück zum Zitat International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRef International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRef
3.
Zurück zum Zitat Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.PubMedCrossRef Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.PubMedCrossRef
4.
Zurück zum Zitat Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.PubMedCrossRef Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.PubMedCrossRef
5.
Zurück zum Zitat Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904–6.PubMedCrossRef Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904–6.PubMedCrossRef
6.
Zurück zum Zitat Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82:1468–73.PubMedCrossRef Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82:1468–73.PubMedCrossRef
7.
Zurück zum Zitat Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52, 802 persons in Nagasaki City. Japan Mayo Clin Proc. 2007;82:1474–9.CrossRef Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52, 802 persons in Nagasaki City. Japan Mayo Clin Proc. 2007;82:1474–9.CrossRef
8.
Zurück zum Zitat Lee LN, Jan IS, Tien HF, Lin JS, Lo SC, Cheng WC. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese. J Formos Med Assoc. 2002;101:91–7.PubMed Lee LN, Jan IS, Tien HF, Lin JS, Lo SC, Cheng WC. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese. J Formos Med Assoc. 2002;101:91–7.PubMed
9.
Zurück zum Zitat Munshi NC. Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc. 2007;82:1457–9.PubMedCrossRef Munshi NC. Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc. 2007;82:1457–9.PubMedCrossRef
10.
Zurück zum Zitat Iwanaga M, Tagawa M, Tsukasaki K, Matsuo T, Yokota K, Miyazaki Y, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood. 2009;113:1639–50.PubMedCrossRef Iwanaga M, Tagawa M, Tsukasaki K, Matsuo T, Yokota K, Miyazaki Y, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood. 2009;113:1639–50.PubMedCrossRef
11.
Zurück zum Zitat Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol. 2002;97:1371–4.PubMedCrossRef Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol. 2002;97:1371–4.PubMedCrossRef
12.
Zurück zum Zitat Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437–44.PubMed Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437–44.PubMed
13.
Zurück zum Zitat Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol. 1982;35:63–8.PubMedCrossRef Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol. 1982;35:63–8.PubMedCrossRef
14.
Zurück zum Zitat Ogmundsdóttir HM, Haraldsdóttir V, Jóhannesson M G, Olafsdóttir G, Bjarnadóttir K, Sigvaldason H, et al. Monoclonal gammopathy in Iceland: a population-based registry and follow-up. Br J Haematol. 2002;118:166–73.PubMedCrossRef Ogmundsdóttir HM, Haraldsdóttir V, Jóhannesson M G, Olafsdóttir G, Bjarnadóttir K, Sigvaldason H, et al. Monoclonal gammopathy in Iceland: a population-based registry and follow-up. Br J Haematol. 2002;118:166–73.PubMedCrossRef
15.
Zurück zum Zitat Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691–7.PubMedCrossRef Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691–7.PubMedCrossRef
16.
Zurück zum Zitat Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998;104:439–44 [published correction appears in Am J Med. 1998;105(4):362]. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998;104:439–44 [published correction appears in Am J Med. 1998;105(4):362].
18.
Zurück zum Zitat Lee JH, Lee DS, Lee JJ, Chang YH, Jin JY, Jo DY, et al. Multiple myeloma in Korea: past, present, and future perspectives Experience of the Korean Multiple Myeloma Working Party. Int J Hematol. 2010;92:52–7.PubMedCrossRef Lee JH, Lee DS, Lee JJ, Chang YH, Jin JY, Jo DY, et al. Multiple myeloma in Korea: past, present, and future perspectives Experience of the Korean Multiple Myeloma Working Party. Int J Hematol. 2010;92:52–7.PubMedCrossRef
19.
Zurück zum Zitat Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812–7.PubMedCrossRef Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812–7.PubMedCrossRef
20.
Zurück zum Zitat Pasqualetti P, Collacciani A, Casale R. Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am J Hematol. 1996;52:217–20.PubMedCrossRef Pasqualetti P, Collacciani A, Casale R. Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am J Hematol. 1996;52:217–20.PubMedCrossRef
21.
Zurück zum Zitat Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113:6386–91.PubMedCrossRef Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113:6386–91.PubMedCrossRef
Metadaten
Titel
Prevalence of monoclonal gammopathy of undetermined significance in Thailand
verfasst von
Phandee Watanaboonyongcharoen
Thanyaphong Na Nakorn
Ponlapat Rojnuckarin
Panisinee Lawasut
Tanin Intragumtornchai
Publikationsdatum
01.02.2012
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2012
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0995-4

Weitere Artikel der Ausgabe 2/2012

International Journal of Hematology 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.